Puma Biotechnology (PBYI)
Market Price (2/2/2026): $6.485 | Market Cap: $326.5 MilSector: Health Care | Industry: Biotechnology
Puma Biotechnology (PBYI)
Market Price (2/2/2026): $6.485Market Cap: $326.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 11%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 7.2%, FCF Yield is 13% | Weak multi-year price returns2Y Excs Rtn is -8.8%, 3Y Excs Rtn is -32% | Stock price has recently run up significantly6M Rtn6 month market price return is 111%, 12M Rtn12 month market price return is 124% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.5%, Rev Chg QQuarterly Revenue Change % is -32% | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% | Key risksPBYI key risks include [1] heavy reliance on its single product, Show more. | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 11%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 7.2%, FCF Yield is 13% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -8.8%, 3Y Excs Rtn is -32% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 111%, 12M Rtn12 month market price return is 124% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.5%, Rev Chg QQuarterly Revenue Change % is -32% |
| Key risksPBYI key risks include [1] heavy reliance on its single product, Show more. |
Stock Movement Drivers
Fundamental Drivers
The 27.1% change in PBYI stock from 10/31/2025 to 2/1/2026 was primarily driven by a 68.6% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.10 | 6.48 | 27.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 238 | 212 | -10.9% |
| Net Income Margin (%) | 20.4% | 17.4% | -14.3% |
| P/E Multiple | 5.2 | 8.8 | 68.6% |
| Shares Outstanding (Mil) | 50 | 50 | -1.3% |
| Cumulative Contribution | 27.1% |
Market Drivers
10/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PBYI | 27.1% | |
| Market (SPY) | 1.5% | -9.0% |
| Sector (XLV) | 7.3% | 9.7% |
Fundamental Drivers
The 108.4% change in PBYI stock from 7/31/2025 to 2/1/2026 was primarily driven by a 117.7% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.11 | 6.48 | 108.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 233 | 212 | -8.9% |
| Net Income Margin (%) | 16.4% | 17.4% | 6.6% |
| P/E Multiple | 4.1 | 8.8 | 117.7% |
| Shares Outstanding (Mil) | 50 | 50 | -1.5% |
| Cumulative Contribution | 108.4% |
Market Drivers
7/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PBYI | 108.4% | |
| Market (SPY) | 9.8% | -1.1% |
| Sector (XLV) | 19.2% | 17.2% |
Fundamental Drivers
The 124.2% change in PBYI stock from 1/31/2025 to 2/1/2026 was primarily driven by a 82.8% change in the company's Net Income Margin (%).| (LTM values as of) | 1312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.89 | 6.48 | 124.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 244 | 212 | -13.0% |
| Net Income Margin (%) | 9.5% | 17.4% | 82.8% |
| P/E Multiple | 6.1 | 8.8 | 44.8% |
| Shares Outstanding (Mil) | 49 | 50 | -2.6% |
| Cumulative Contribution | 124.2% |
Market Drivers
1/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PBYI | 124.2% | |
| Market (SPY) | 16.0% | 15.3% |
| Sector (XLV) | 6.8% | 27.5% |
Fundamental Drivers
The 50.7% change in PBYI stock from 1/31/2023 to 2/1/2026 was primarily driven by a 286.2% change in the company's Net Income Margin (%).| (LTM values as of) | 1312023 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.30 | 6.48 | 50.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 218 | 212 | -2.6% |
| Net Income Margin (%) | 4.5% | 17.4% | 286.2% |
| P/E Multiple | 19.9 | 8.8 | -55.7% |
| Shares Outstanding (Mil) | 46 | 50 | -9.5% |
| Cumulative Contribution | 50.7% |
Market Drivers
1/31/2023 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PBYI | 50.7% | |
| Market (SPY) | 76.6% | 17.8% |
| Sector (XLV) | 21.4% | 21.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PBYI Return | -70% | 39% | 2% | -30% | 95% | 8% | -37% |
| Peers Return | -16% | -28% | -41% | -66% | -32% | 6% | -91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| PBYI Win Rate | 33% | 33% | 58% | 50% | 58% | 100% | |
| Peers Win Rate | 36% | 50% | 53% | 29% | 56% | 100% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| PBYI Max Drawdown | -72% | -46% | -48% | -48% | -10% | -3% | |
| Peers Max Drawdown | -30% | -45% | -60% | -67% | -49% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ACSB, AKTS, ALPS, APRI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/30/2026 (YTD)
How Low Can It Go
| Event | PBYI | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -88.0% | -25.4% |
| % Gain to Breakeven | 730.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -56.9% | -33.9% |
| % Gain to Breakeven | 131.9% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -95.1% | -19.8% |
| % Gain to Breakeven | 1937.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to VRTX, ACSB, AKTS, ALPS, APRI
In The Past
Puma Biotechnology's stock fell -88.0% during the 2022 Inflation Shock from a high on 2/9/2021. A -88.0% loss requires a 730.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Puma Biotechnology (PBYI)
AI Analysis | Feedback
- Like a specialized Genentech focused on HER2-positive breast cancer.
- A smaller, targeted Amgen for oncology.
AI Analysis | Feedback
- Nerlynx (neratinib): An oral irreversible tyrosine kinase inhibitor used for the extended adjuvant treatment of early-stage HER2-positive breast cancer and for HER2-positive metastatic breast cancer.
AI Analysis | Feedback
Major Customers of Puma Biotechnology (PBYI)
Puma Biotechnology (PBYI) is a biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer. As is typical for pharmaceutical companies, Puma Biotechnology sells its products primarily to a limited number of wholesale pharmaceutical distributors, rather than directly to individuals. These distributors then supply hospitals, pharmacies, and other healthcare providers. According to Puma Biotechnology's SEC filings, a concentrated number of wholesale pharmaceutical distributors account for substantially all of their revenue. For the year ended December 31, 2023, these major customers were:- McKesson Corporation (NYSE: MCK)
- AmerisourceBergen Corporation (now Cencora, Inc. NYSE: COR)
- Cardinal Health, Inc. (NYSE: CAH)
AI Analysis | Feedback
- Dishman Carbogen Amcis Ltd. (Symbol: DISHMAN)
- Thermo Fisher Scientific (Symbol: TMO)
AI Analysis | Feedback
Alan H. Auerbach, Chief Executive Officer, President, and Chairman
Mr. Auerbach is the Founder of Puma Biotechnology, Inc. He has served as its Executive Chairman since October 2011 and as Chief Executive Officer, President, and Secretary since September 2010. Prior to founding Puma, he founded Cougar Biotechnology Inc. in May 2003, serving as its Chief Executive Officer, President, and a board member until its acquisition by Johnson & Johnson in July 2009 for approximately $1 billion. Before founding Cougar, Mr. Auerbach was a Vice President and Senior Research Analyst at Wells Fargo Securities, covering small and mid-capitalization biotechnology companies with a focus on oncology. He is also noted as a Private Equity Partner at Burrill Private Equity.
Maximo F. Nougues, Chief Financial Officer
Mr. Nougues joined Puma Biotechnology as Chief Financial Officer in November 2018. Before Puma, he worked at Getinge AB, a global medical device company, from January 2008 to October 2018, holding leadership positions including regional chief financial officer for North America and the Americas. Earlier in his career, Mr. Nougues held finance roles in Boston Scientific's cardiac surgery division (which was acquired by Getinge in 2008) and at The Clorox Company from 1998 to 2007.
Douglas Hunt, Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer
Mr. Hunt has been Puma Biotechnology's Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer since April 2024. Prior to this role, he served as Senior Vice President, Regulatory Affairs at Puma Biotechnology. His previous experience includes serving as Vice President Regulatory Affairs and Quality Assurance at ArmaGen Inc.
Heather J. Blaber, Senior Vice President, Marketing
Ms. Blaber is the Senior Vice President of Marketing at Puma Biotechnology.
Gordon Esplin, Chief Accounting Officer
Mr. Esplin serves as the Chief Accounting Officer for Puma Biotechnology.
AI Analysis | Feedback
The following are the key risks to Puma Biotechnology (PBYI):
-
Heavy Reliance on NERLYNX and Intense Market Competition: Puma Biotechnology's financial health is predominantly tied to the sales of its single commercial product, NERLYNX, for HER2-positive breast cancer. This creates a significant vulnerability as approximately 95.2% of its total revenue in Q3 2025 came from NERLYNX product sales. The market for HER2-positive breast cancer treatments is highly competitive, with numerous established therapies and newer, more potent antibody-drug conjugates (e.g., trastuzumab deruxtecan) posing a constant threat to NERLYNX's market share. This intense competition and the potential for declining new patient enrollments could limit future revenue growth. Furthermore, international royalty revenue, a component of overall revenue, experienced a sharp decline in Q3 2025, dropping from $24.4 million in Q3 2024 to $2.6 million in Q3 2025, primarily due to reduced product supply to international licensees.
-
Uncertainty and Development Risk of Pipeline Drug Alisertib: Puma Biotechnology's long-term growth strategy relies heavily on the successful development and commercialization of its pipeline drug, alisertib, an Aurora kinase A inhibitor. However, alisertib is in early-stage development, and its commercial viability remains unproven, contingent on positive data from ongoing Phase II ALISCA-Breast1 and ALISCA-Lung1 trials, with key interim data readouts anticipated in the first half of 2026. Alisertib has a "spotty development history," and concerns exist regarding its clinical viability due to previous clinical failures by Takeda. Failure of these ongoing clinical studies could lead to significant delays, increased expenditures, or even the cessation of further development, jeopardizing a crucial future revenue stream for the company.
-
Legal and Regulatory Challenges, particularly Patent Invalidity: Puma Biotechnology is exposed to legal and regulatory risks that could impact its commercial prospects. A significant development occurred in August 2024 when a federal court ruled that some of Puma's patents ('314 and '162), which are exclusively licensed to Puma and cover aspects of NERLYNX, were invalid in a dispute with AstraZeneca. The court found these patents invalid due to a lack of enablement and written description for a specific claim limitation. While Puma retains contractual rights to monetary damages from the AstraZeneca litigation, this partial loss of patent validity could expose the company to increased competition and limit its ability to protect its intellectual property for NERLYNX. Additionally, the company faces ongoing risks related to obtaining and maintaining orphan drug designations and navigating extensive and evolving regulatory requirements in the United States and internationally for all its drug candidates.
AI Analysis | Feedback
The continued and expanding market penetration and demonstrated superior efficacy of Enhertu (trastuzumab deruxtecan) in HER2-positive breast cancer. Enhertu, a next-generation antibody-drug conjugate from Daiichi Sankyo and AstraZeneca, has shown superior clinical outcomes in multiple trials, including direct comparisons with existing treatments. Its strong clinical profile across various lines of therapy in metastatic HER2-positive breast cancer and its ongoing development into earlier treatment settings are actively reshaping the standard of care for patients, thereby posing a direct and significant threat to the market share and utility of other HER2-targeted therapies, including Puma Biotechnology's lead product, NERLYNX (neratinib).
AI Analysis | Feedback
Puma Biotechnology's main product is NERLYNX (neratinib), an oral medication used to treat HER2-positive breast cancer. The global addressable market for neratinib was valued at approximately USD 1.3 billion in 2023 and is projected to grow to USD 3.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.7% during this forecast period.
North America currently holds the largest share of the neratinib market, with Europe also representing a significant portion. The Asia Pacific region is anticipated to experience the fastest growth in this market.
AI Analysis | Feedback
Puma Biotechnology (PBYI) is expected to drive future revenue growth over the next two to three years through several key initiatives and market dynamics:
- Increased U.S. Demand and Sales Volume for NERLYNX: The company anticipates 2025 to be the first year since 2018 to see a year-over-year increase in demand for NERLYNX in the United States. This is supported by an 8% increase in NERLYNX bottle sales volume in the U.S. market in Q3 2025, alongside a higher net selling price. Management commentary indicates stronger growth in the specialty pharmacy (SD) channel due to increased sales in group purchasing organizations and 340B purchasing.
- Strategic Commercial Efforts and Pricing Power for NERLYNX: Puma Biotechnology is focusing on enhancing its commercial execution in the U.S. market. This includes efforts to increase healthcare provider reach and engagement, prioritize NERLYNX for patients at higher risk of recurrence, and improve clinical education through promotional activities and patient support. The company has also demonstrated strong pricing power, indicated by a favorable gross-to-net adjustment.
- Expansion of NERLYNX into New International Markets: Puma is actively pursuing partnerships to expand the global reach of NERLYNX. A recent collaboration with Er-Kim aims to distribute NERLYNX in ten countries across Europe, the Middle East, and Africa (EMEA), which is expected to support global revenue growth.
- Advancement and Potential Approval of Alisertib in New Indications: The company is investing in its clinical pipeline, particularly with alisertib, an anti-cancer drug. Puma is conducting Phase II trials for alisertib as a monotherapy for extensive-stage small cell lung cancer (ALISCA-Lung1) and in breast cancer (ALISCA-Breast1). Interim data from the ALISCA-Lung1 study is anticipated in the first half of 2026. Successful outcomes and subsequent regulatory approvals for these new indications would open significant new market opportunities.
- Enhanced Financial Flexibility from Becoming Debt-Free: While not a direct revenue driver, Puma Biotechnology anticipates becoming debt-free by mid-2026. This improved financial position is expected to enhance cash flow generation, which can then be strategically reinvested into research and development, supporting future clinical trials for pipeline products like alisertib, and further commercialization efforts for NERLYNX, thereby indirectly fueling future revenue growth.
AI Analysis | Feedback
Share Repurchases
- Puma Biotechnology did not report any share repurchases from 2020 to 2024.
Share Issuance
- The number of common shares outstanding for Puma Biotechnology increased from 39.88 million at the end of 2020 to 49.09 million at the end of 2024.
- As of November 3, 2025, the company had 50,391,107 shares of common stock outstanding.
- Historically, public offerings of common stock and sales of common stock in private placements have been sources of working capital for Puma Biotechnology.
Inbound Investments
- In September 2022, Puma Biotechnology entered into an exclusive license agreement for the global development and commercialization of the anti-cancer drug alisertib.
- This licensing deal included an upfront payment of $7.0 million, which was recognized as an in-process research and development expense in 2022.
Outbound Investments
- Puma Biotechnology reported no cash acquisitions of other companies from 2020 to 2024.
Capital Expenditures
- Capital expenditures were $0.0 million for the years 2020, 2021, and 2022.
- Capital expenditures were $0.1 million for both 2023 and 2024.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Puma Biotechnology Earnings Notes | 12/16/2025 | |
| Puma Biotechnology Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.37 |
| Mkt Cap | 60.2 |
| Rev LTM | 5,968 |
| Op Inc LTM | -29 |
| FCF LTM | 1,690 |
| FCF 3Y Avg | 1,047 |
| CFO LTM | 1,880 |
| CFO 3Y Avg | 1,226 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.3% |
| Rev Chg 3Y Avg | 5.0% |
| Rev Chg Q | -10.7% |
| QoQ Delta Rev Chg LTM | -4.1% |
| Op Mgn LTM | 7.5% |
| Op Mgn 3Y Avg | 20.0% |
| QoQ Delta Op Mgn LTM | -1.3% |
| CFO/Rev LTM | 26.0% |
| CFO/Rev 3Y Avg | 19.0% |
| FCF/Rev LTM | 24.3% |
| FCF/Rev 3Y Avg | 16.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 60.2 |
| P/S | 5.9 |
| P/EBIT | 17.6 |
| P/E | 20.8 |
| P/CFO | 19.9 |
| Total Yield | 7.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 8.0% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.5% |
| 3M Rtn | 10.4% |
| 6M Rtn | 2.1% |
| 12M Rtn | 63.2% |
| 3Y Rtn | 51.5% |
| 1M Excs Rtn | 6.9% |
| 3M Excs Rtn | 11.9% |
| 6M Excs Rtn | -6.6% |
| 12M Excs Rtn | 43.9% |
| 3Y Excs Rtn | -27.7% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA208051 | NERLYNX | neratinib maleate | tablet | 7172017 | 44.2% | 15.3% | -39.0% | -87.8% | -92.5% |
Price Behavior
| Market Price | $6.48 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 04/20/2012 | |
| Distance from 52W High | -6.0% | |
| 50 Days | 200 Days | |
| DMA Price | $5.81 | $4.53 |
| DMA Trend | up | up |
| Distance from DMA | 11.6% | 43.0% |
| 3M | 1YR | |
| Volatility | 75.6% | 71.0% |
| Downside Capture | -38.78 | 40.22 |
| Upside Capture | 104.84 | 117.29 |
| Correlation (SPY) | -9.7% | 15.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.71 | 0.13 | -0.60 | -0.14 | 0.57 | 0.86 |
| Up Beta | 6.01 | 3.68 | -5.23 | -1.17 | 0.34 | 0.52 |
| Down Beta | -1.99 | -1.08 | -0.14 | -0.11 | 0.58 | 0.69 |
| Up Capture | -25% | 168% | 105% | 130% | 129% | 129% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 11 | 25 | 33 | 70 | 127 | 362 |
| Down Capture | -287% | -154% | -43% | -131% | 57% | 104% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 9 | 16 | 27 | 54 | 118 | 369 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PBYI | |
|---|---|---|---|---|
| PBYI | 112.9% | 71.1% | 1.35 | - |
| Sector ETF (XLV) | 7.7% | 17.2% | 0.27 | 27.3% |
| Equity (SPY) | 16.1% | 19.2% | 0.65 | 15.4% |
| Gold (GLD) | 76.5% | 23.4% | 2.38 | -5.8% |
| Commodities (DBC) | 11.1% | 15.9% | 0.48 | -6.3% |
| Real Estate (VNQ) | 5.3% | 16.5% | 0.14 | 22.8% |
| Bitcoin (BTCUSD) | -18.9% | 39.9% | -0.43 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PBYI | |
|---|---|---|---|---|
| PBYI | -12.3% | 75.4% | 0.16 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 21.5% |
| Equity (SPY) | 14.0% | 17.1% | 0.65 | 21.9% |
| Gold (GLD) | 20.8% | 16.5% | 1.03 | 2.3% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | 4.2% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 18.5% |
| Bitcoin (BTCUSD) | 21.1% | 57.5% | 0.56 | 15.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PBYI | |
|---|---|---|---|---|
| PBYI | -17.6% | 81.6% | 0.14 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 28.2% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 26.2% |
| Gold (GLD) | 15.6% | 15.3% | 0.85 | -1.7% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 10.1% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 17.9% |
| Bitcoin (BTCUSD) | 71.5% | 66.4% | 1.11 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 22.2% | 1.0% | 12.7% |
| 8/7/2025 | 12.2% | 61.7% | 38.6% |
| 5/8/2025 | -5.2% | 6.8% | 17.3% |
| 2/27/2025 | 19.7% | 20.9% | 5.0% |
| 11/7/2024 | -5.0% | -1.3% | -3.6% |
| 8/1/2024 | 9.4% | 9.4% | -28.6% |
| 2/29/2024 | -5.3% | -7.6% | -15.1% |
| 11/2/2023 | 11.6% | 32.9% | 52.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 15 | 12 |
| # Negative | 9 | 6 | 9 |
| Median Positive | 11.9% | 9.4% | 18.2% |
| Median Negative | -5.3% | -17.9% | -21.1% |
| Max Positive | 26.6% | 61.7% | 101.4% |
| Max Negative | -37.2% | -45.2% | -53.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/03/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Miller, Michael Patrick | Direct | Sell | 11132025 | 4.86 | 20,000 | 97,228 | 262,516 | Form | |
| 2 | Cesano, Alessandra | Direct | Sell | 7222025 | 3.37 | 27,000 | 90,909 | 140,909 | Form | |
| 3 | Nougues, Maximo F | Chief Financial Officer | Direct | Sell | 7102025 | 3.53 | 5,587 | 19,739 | 735,443 | Form |
| 4 | Nougues, Maximo F | Chief Financial Officer | Direct | Sell | 7102025 | 3.54 | 3,935 | 13,910 | 721,950 | Form |
| 5 | Hunt, Douglas M | See Remarks | Direct | Sell | 7102025 | 3.53 | 4,374 | 15,453 | 594,735 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.